Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinom

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Dec 23, 2024 1:25pm

169 Views

Post# 36375316

RE:RE:RE:BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinom

Yes, a pre-BTD meeting late December followed by BTD submission in Q1 is what it sounded like. Will know soon enough if the story has changed again. You would think the FDA has all the info it needs by now, especially given the FTD status since 2020. But we've been here before.

bmk211 wrote: I thought per the zoom call they were submitting a pre btd. It's not pass or fail for that probably no news to give regarding a pre btd. The BTD they said would be submitted early 2025 I thought.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks